|

Deep Learning on Amyloid Positons Emission Tomography

RECRUITINGSponsored by Central Hospital, Nancy, France
Actively Recruiting
SponsorCentral Hospital, Nancy, France
Started2026-05-06
Est. completion2026-11-20
Eligibility
Age18 Years – 99 Years
View on ClinicalTrials.gov →

NCT07309107

Summary

Reducing injected dose and/or acquisition time in amyloid PET imaging would improve comfort, radiation safety and cost-effectiveness in diagnosis and follow-up of patients. This study evaluates the impact of a deep learning-based noise reduction algorithm on visual analysis and Centiloid quantification when simulating reduced injected doses of \[18F\]flutemetamol.

Eligibility

Age: 18 Years – 99 Years
Inclusion Criteria:

* Patients with objective cognitive impairment,
* Referred to our department for a cerebral \[¹⁸F\]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025,

Exclusion Criteria:

* Patient have objected to the use of their data.

Conditions2

Alzheimer DiseaseAlzheimer's Disease

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.